GlassScriptPhysician profile
Jesse Wood
NPI 1063086486
$1,478.71
in general payments reported to CMS, 2019-2025
14 companies · $920 in 2025
The $920 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $94.94 · 2024: $464 · 2025: $920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,349 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,348.73 |
| Education | $129.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $221.11 | 2025 | |
| Janssen Scientific Affairs, LLC | $203.11 | 2025 | |
| Ucb, INC. | $197.97 | 2025 | Bimzelx |
| Abbvie INC. | $193.86 | 2024-2025 | |
| Janssen Biotech, INC. | $129.98 | 2024-2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $113.19 | 2024-2025 | Saphnelo |
| Amgen INC. | $103.87 | 2024-2025 | Enbrel, Otezla, Enbrel |
| Astellas Pharma US INC | $98.65 | 2024 | Veozah |
| Glaxosmithkline, LLC. | $77.38 | 2024 | Benlysta |
| Medtronic, INC. | $55.64 | 2023 | Selectsecure |
| Lilly USA, LLC | $25.46 | 2024 | Jardiance |
| Novo Nordisk INC | $22.29 | 2023 | Rybelsus, Ozempic |
| Chiesi USA, INC. | $19.19 | 2024 | Myalept |
| Mannkind Corporation | $17.01 | 2023 | Afrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Wood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.